HERB-DH1关键试验:数字疗法管理原发性高血压的疗效
HERB-DH1关键试验是一项在日本12个中心开展的前瞻性、开放标签、随机对照研究,纳入390例未接受降压药物治疗的高血压患者,随机分为数字疗法组(HERB系统+标准生活方式调整)或对照组(仅标准生活方式调整)。主要终点为12周时24小时动态收缩压较基线的平均变化,结果显示数字疗法组在24小时动态、家庭和诊室收缩压降低方面均优于对照组,且至24周未发生重大程序相关安全事件。
要点
- 数字疗法联合标准生活方式调整可显著降低未用药高血压患者的24小时动态、家庭和诊室收缩压。
- 12周时组间24小时动态收缩压差异为-2.4 mmHg(95%CI -4.5至-0.3)。
- 至24周未发生重大程序相关安全事件。
核心结论
- 在未接受降压药物治疗的高血压患者中,数字疗法联合标准生活方式调整在降低24小时动态、家庭和诊室血压方面优于单纯标准生活方式调整。
研究设计与样本
- 前瞻性、开放标签、随机对照研究,在日本12个中心开展。
- 纳入诊室收缩压140至<180 mmHg且24小时动态收缩压≥130 mmHg的高血压患者390例,按1:1随机分配至数字疗法组(n=199)或对照组(n=191)。
- 主要终点为12周时24小时动态收缩压较基线的平均变化,关键次要终点为12周时诊室和家庭血压较基线的平均变化,全分析集进行分析。
主要发现
- 12周时,数字疗法组与对照组24小时动态收缩压的组间差异为-2.4 mmHg(95%CI -4.5至-0.3)。
- 12周时,家庭收缩压的组间差异为-4.3 mmHg(95%CI -6.7至-1.9)。
- 12周时,诊室收缩压的组间差异为-3.6 mmHg(95%CI -6.2至-1.0)。
- 至24周未发生重大程序相关安全事件。
临床怎么用
- 对于未接受降压药物治疗的高血压患者,可考虑使用数字疗法系统辅助标准生活方式调整,以进一步降低动态、家庭和诊室血压。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Digital therapeutics is a new approach to facilitate the non-pharmacological treatment of hypertension using software programmes such as smartphone applications and/or device algorithms. Based on promising findings from a small pilot trial, the HERB Digital Hypertension 1 (HERB-DH1) pivotal trial investigated the efficacy of digital therapeutics in patients with hypertension not receiving antihypertensive medication. METHODS AND RESULTS: This prospective, open-label, randomized controlled study was performed at 12 sites in Japan. Patients with hypertension [office systolic blood pressure (SBP) 140 to <180 mmHg and 24 h SBP ≥130 mmHg] were randomly assigned 1:1 to the digital therapeutics group (HERB system + standard lifestyle modification) or control group (standard lifestyle modification alone). The primary efficacy endpoint was the mean change in 24 h ambulatory SBP from baseline to 12 weeks; key secondary efficacy endpoints were mean changes in office and home blood pressure (BP) from baseline to 12 weeks. All analyses were conducted in the full analysis set population. Between December 2019 and June 2020, 390 patients were randomly assigned to the digital therapeutics group (n = 199) or control (n = 191) group. Between-group differences in 24-h ambulatory, home, and office SBPs at 12 weeks were -2.4 (95% confidence interval -4.5 to -0.3), -4.3 (-6.7 to -1.9), and -3.6 (-6.2 to -1.0) mmHg, respectively. No major programme-related safety events occurred up to 24 weeks. CONCLUSION: The HERB-DH1 pivotal study showed the superiority of digital therapeutics compared with standard lifestyle modification alone to reduce 24-h ambulatory, home, and office BPs in the absence of antihypertensive medications.
引用
- Kario K, Nomura A, Harada N, et al. Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial. Eur Heart J. 2021. PMID: 34455443. doi:10.1093/eurheartj/ehab559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。